Mutations in IDH1/2 Seen in Intrahepatic Bile Duct Cancers

Share this article:
Mutations in <i>IDH1/2</i> Seen in Intrahepatic Bile Duct Cancers
Mutations in IDH1/2 Seen in Intrahepatic Bile Duct Cancers

THURSDAY, Jan. 26 (HealthDay News) -- Mutations in genes encoding isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are present in about a quarter of biliary tract carcinomas arising within the liver, according to a study published online Dec. 16 in The Oncologist.

Darrell R. Borger, Ph.D., from the Massachusetts General Hospital Cancer Center in Boston, and colleagues performed genotyping of 287 gastrointestinal tumors (biliary tract, colorectal, gastroesophageal, liver, pancreatic, and small intestine) for 130 known cancer-specific mutations within 15 cancer genes.

The researchers found that, while mutations in IDH1 were only present in 2 percent of all tumors, they were present in 25 percent of 12 biliary tract carcinomas. Further screening of an additional 75 gallbladder and bile duct cancers showed that mutations in IDH1 and IDH2 were present in 23 percent of cholangiocarcinomas of intrahepatic origin, but in none of the extrahepatic cholangiocarcinomas or gallbladder carcinomas. IDH1 mutation was associated with highly elevated levels of 2-hydroxyglutarate in an analysis of frozen tissue specimens.

"Thus, IDH1 mutation is a molecular feature of cholangiocarcinomas of intrahepatic origin. These findings define a specific metabolic abnormality in this largely incurable type of gastrointestinal cancer and present a potentially new target for therapy," the authors write.

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries. Two authors hold intellectual property rights to the SNaPshot Genotyping Assay used in the study; one author is a co-inventor of discovery of neoactivity of IDH1 and IDH2 mutations.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Market changes needed as patients take on greater care costs

Market changes needed as patients take on greater ...

As consumers take on more costs of care, access to data for informed decisions is deemed crucial.

For black men with prostate cancer, watchful waiting may be unwise

For black men with prostate cancer, watchful waiting ...

For men with early-stage prostate cancer, watching waiting is not always the best course of action, especially for black patients.

Half of staff feel dignified death is a possibility in cancer centers

Half of staff feel dignified death is a ...

Compared with staff from other wards, palliative care staff reported much better conditions for the dying, with 95 percent indicating that patients die with dignity in palliative care wards.